Aprea Therapeutics is a pharmaceutical development company that is engaged in the discovery and development of anticancer compounds targeting tumour suppressor proteins. The company offers p53, a tumor suppressor protein that responds to various forms of cellular stresses and activates transcription of genes that induce cell cycle arrest or apoptosis; APR-246 that reactivates mutant and defective native p53, leading to tumor cell death; and APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.